



## Rabbit Anti-phospho-TGF beta Receptor II (Ser225) antibody

SL20300R

<b>Product Name:</b>	phospho-TGF beta Receptor II (Ser225)
<b>Chinese Name:</b>	磷酸化转移生长因子β受体2抗体
<b>Alias:</b>	TGF beta Receptor II (phospho Ser225); p-TGF beta Receptor II (phospho S225); TGF beta Receptor II (phospho Ser225); p-TGFβ RII (Ser225); AAT3; FAA3; LDS1B; LDS2B; MFS2; RIIC; TAAD2; TbetaR II; TbetaR-II; TGF beta receptor type II; TGF beta receptor type IIB; TGF beta type II receptor; TGF-beta receptor type II; TGF-beta receptor type-2; TGF-beta type II receptor; TGFB R2; TGFbeta - RII; TGFbeta RII; TGFB R2; TGFR-2; TGFR2_HUMAN; Transforming growth factor beta receptor II; Transforming growth factor beta receptor type II; Transforming growth factor beta receptor type IIC; Transforming growth factor, beta receptor II (70/80kDa); Transforming growth factor-beta receptor type II.
<b>Organism Species:</b>	Rabbit
<b>Clonality:</b>	Polyclonal
<b>React Species:</b>	Human,Mouse,Rat,Dog,Pig,Rabbit,Sheep,
<b>Applications:</b>	WB=1:500-2000ELISA=1:500-1000IHC-P=1:400-800IHC-F=1:400-800ICC=1:100-500IF=1:100-500 (Paraffin sections need antigen repair) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
<b>Molecular weight:</b>	62kDa
<b>Cellular localization:</b>	The cell membrane
<b>Form:</b>	Lyophilized or Liquid
<b>Concentration:</b>	1mg/ml
<b>immunogen:</b>	KLH conjugated synthesised phosphopeptide derived from human TGF beta Receptor II around the phosphorylation site of Ser225:DR(p-S)DI
<b>Lsotype:</b>	IgG
<b>Purification:</b>	affinity purified by Protein A
<b>Storage Buffer:</b>	Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
<b>Storage:</b>	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized

	antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
<b>PubMed:</b>	<a href="#">PubMed</a>
<b>Product Detail:</b>	<p>This gene encodes a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. The encoded protein is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized. [provided by RefSeq, Jul 2008]</p> <p><b>Function:</b>  Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.</p> <p><b>Subcellular Location:</b>  Cell membrane.</p> <p><b>Post-translational modifications:</b>  Phosphorylated on a Ser/Thr residue in the cytoplasmic domain.</p> <p><b>DISEASE:</b>  Defects in TGFBR2 are the cause of hereditary non-polyposis colorectal cancer type 6 (HNPCC6) [MIM:614331]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be</p>

the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. HNPCC6 is a type of colorectal cancer complying with the clinical criteria of HNPCC, except that the onset of cancer was beyond 50 years of age in all cases. Defects in TGFBR2 are a cause of esophageal cancer (ESCR) [MIM:133239]. Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 1B (LDS1B) [MIM:610168]. LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropia, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.

**Similarity:**

Belongs to the protein kinase superfamily.

TKL Ser/Thr protein kinase family.

TGFB receptor subfamily.

Contains 1 protein kinase domain.

**SWISS:**

P37173

**Gene ID:**

7048

**Database links:**

[Entrez Gene: 7048](#)Human

[Entrez Gene: 21813](#)Mouse

[Omim: 190182](#)Human

[SwissProt: P37173](#)Human

[SwissProt: Q62312](#)Mouse

[Unigene: 604277](#)Human


[Unigene: 82028](#)Human

[Unigene: 172346](#)Mouse

**Important Note:**

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

**Picture:**



Sample:


Spleen (Mouse) Lysate at 40 ug

Primary: Anti- p-TGF beta Receptor II(Ser225) (SL20300R)at 1/300 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 62 kD

Observed band size: 64 kD



Sample:


Lung (Mouse) Lysate at 40 ug

Primary: Anti- p-TGF beta Receptor II(Ser225) (SL20300R)at 1/300 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 62 kD

Observed band size: 64 kD



Sample:

Lymph node (Mouse) Lysate at 40 ug

Primary: Anti- p-TGF beta Receptor II(Ser225) (SL20300R) at 1/300 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 62 kD

Observed band size: 64 kD